Reports
Reports
Sale
The HIV drug market size attained a value of USD 33.54 billion in 2023. The market is anticipated to grow at a CAGR of 4.5% during the forecast period of 2024-2032 to attain a value of USD 49.85 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Human immunodeficiency virus (HIV) is a life-threatening condition that can be transferred from one person to another through blood and/or sexual contact. It damages the immune system by destroying CD-4 cells, making the body susceptible to infections and other diseases. The rising prevalence of HIV disease has positively impacted the demand for HIV drugs. According to the estimates by the World Health Organization (WHO), 39 million people are living with HIV. Approximately 0.7% of adults aged between 15-49 years are living with this condition worldwide. The growing population density of HIV-infected people has been instrumental in the development and introduction of HIV drugs.
The HIV drugs market growth is influenced by the rising government initiatives and campaigns to create awareness amongst people regarding the causes, symptoms, and treatments of the condition. At present, highly active antiretroviral therapy (HAART) is the most prescribed treatment. It has various combinations of one protease inhibitor and other drugs. These combinations aid in increasing the number of CD4+ cells and decreasing the amount of virus in the blood. The introduction of generic drug acts is another factor that is contributing to the demand for HIV drugs, as they are cost-effective and chemically identical to branded drugs. The market is experiencing increased advancement in the treatment technologies by the market players. Such advancements are significantly expected to drive the market growth.
Expedited Drug Development to Boost HIV Drugs Market Share
In October 2023, Gilead Sciences, Inc. revealed that Sunlenca® (lenacapavir), their latest drug was well supported to treat multi-drug resistant (MDR) HIV in adults. Administered twice a year, Sunlenca is a human immunodeficiency virus type 1 (HIV-1) capsid inhibitor, used in combination with other antiretrovirals. The drug is expected to be made available in oral as well as injectable mode of administration along with multiple dosage forms. The increasing advancements to bring customization and offer precise treatment to patients is poised to drive the market for HIV drugs in the forecast period.
Surge in Clinical Trials to Meet the Rising HIV Drugs Market Demand
The market growth is poised to be driven by the rising number of clinical trials and continued efforts by researchers to discover an effective treatment novel therapy to treat HIV. For instance, in April 2023, UC Davis Health researchers deployed CAR T cell therapy to treat patients suffering from HIV . Leveraging immunotherapy, the first patient was dosed with anti-HIV duoCAR T cells to stimulate the immune system and treat the condition. The clinical trial was designed for 9 candidates, divided in 3 cohorts wherein patients from each cohort underwent different treatment combinations. This is indicative of rising application of advanced and alternative therapies to treat the fatal disease.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Medication Class
Market Breakup by Distribution Channel
Market Breakup by End User
Market Breakup by Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Geographically, North America is expected to lead the market share in the forecast period. The regional growth can be attributed to a well-established healthcare system, and the growing adoption of advanced treatment options for the HIV-infected population. The HIV drugs market size is significantly impacted by the increased number of research and development initiatives for new drug launches.
In September 2023, researchers at Johns Hopkins found a new injectable solution that could help manage HIV, unlike any currently available methods in the market. This new solution self-assembles into a gel under the right conditions. It releases a steady dose of the anti-HIV drug lamivudine over six weeks. The major issue that patients face while following an HIV treatment regimen is the daily management of the doses. However, this new gel treatment is poised to help people living with HIV to have a new therapy that doesn't require a daily pill regimen to prevent AIDS, making it less stressful and easy to follow.
The Asia Pacific region is also poised to experience significant HIV drugs market growth, owing to increasing infrastructure improvements and emphasis on spreading awareness about the condition amongst marginalised communities.
In February 2022, ViiV Healthcare , the global specialist HIV company, announced the US Food and Drug Administration (FDA) approval for Cabenuva (cabotegravir, rilpivirine) for every two months dosing for the treatment of HIV-1 in virologically suppressed adults. The drug constitutes an extended-release injectable suspension in a single vial dose, making it suitable for easy administration. The approval was based on the positive results from ATLAS-2M phase IIIb trial.
The key features of the HIV drugs market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Please note that this only represents a partial list of companies, and the complete list has been provided in the report.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Medication Class |
|
Breakup by Distribution Channel |
|
Breakup by End User |
|
Breakup by Region |
|
Market Dynamics |
|
Competitive Landscape |
|
Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 HIV Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 HIV Epidemiology Analysis – 8 Major Markets
5.1 8MM Epidemiology Scenario Overview (2017-2032)
5.2 United States HIV Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom HIV Epidemiology Forecast (2017-2032)
5.3.1 Germany HIV Epidemiology Forecast (2017-2032)
5.3.2 France HIV Epidemiology Forecast (2017-2032)
5.3.3 Italy HIV Epidemiology Forecast (2017-2032)
5.3.4 Spain HIV Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom HIV Epidemiology Forecast (2017-2032)
5.4 Japan HIV Epidemiology Forecast (2017-2032)
6 HIV Drugs Market Overview – 8 Major Markets
6.1 HIV Drugs Market Historical Value (2017-2023)
6.2 HIV Drugs Market Forecast Value (2024-2032)
7 HIV Drugs Market Landscape – 8 Major Markets
7.1 HIV Drugs: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 HIV Drugs: Product Landscape
7.2.1 Analysis by Type
7.2.2 Analysis by Medication Class
8 HIV Drugs Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 HIV Drugs Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 HIV Drugs Market Segmentation-8 Major Markets
11.1 HIV Drugs Market by Medication Class
11.1.1 Market Overview
11.1.2 Multi-Class Combination Drugs
11.1.3 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
11.1.4 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
11.1.5 Protease Inhibitors (PIs)
11.1.6 Entry Inhibitors
11.1.7 HIV Integrase Strand Transfer Inhibitors
11.1.8 Others
11.2 HIV Drugs Market by Distribution Channel
11.2.1 Market Overview
11.2.2 Hospital Pharmacies
11.2.3 Drugs stores and retail pharmacies
11.2.4 Online pharmacies
11.3 HIV Drugs Market by End User
11.3.1 Market Overview
11.3.2 Hospitals
11.3.3 Clinics
11.3.4 Others
11.4 HIV Drugs Market by Region
11.4.1 Market Overview
11.4.2 United States
11.4.3 EU-4 and the United Kingdom
11.4.3.1 Germany
11.4.3.2 France
11.4.3.3 Italy
11.4.3.4 Spain
11.4.3.5 United Kingdom
11.4.4 Japan
11.4.5 China
12 United States HIV Drugs Market
12.1 HIV Drugs Market Historical Value (2017-2023)
12.2 HIV Drugs Market Forecast Value (2024-2032)
12.3 United States HIV Drugs Market by Medication Class
12.3.1 Market Overview
12.3.2 Multi-Class Combination Drugs
12.3.3 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
12.3.4 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
12.3.5 Protease Inhibitors (PIs)
12.3.6 Entry Inhibitors
12.3.7 HIV Integrase Strand Transfer Inhibitors
12.3.8 Others
12.4 United States HIV Drugs Market by Distribution Channel
12.4.1 Market Overview
12.4.2 Hospital Pharmacies
12.4.3 Drugs stores and retail pharmacies
12.4.4 Online pharmacies
13 EU-4 and United Kingdom HIV Drugs Market
13.1 EU-4 and United Kingdom HIV Drugs Market Historical Value (2017-2023)
13.2 EU-4 and United Kingdom HIV Drugs Market Forecast Value (2024-2032)
13.3 EU-4 and United Kingdom HIV Drugs Market Overview
13.4 EU-4 and United Kingdom HIV Drugs Market by Medication Class
13.4.1 Market Overview
13.4.2 Multi-Class Combination Drugs
13.4.3 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
13.4.4 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
13.4.5 Protease Inhibitors (PIs)
13.4.6 Entry Inhibitors
13.4.7 HIV Integrase Strand Transfer Inhibitors
13.4.8 Others
13.5 EU-4 and United Kingdom HIV Drugs Market by Distribution Channel
13.5.1 Market Overview
13.5.2 Hospital Pharmacies
13.5.3 Drugs stores and retail pharmacies
13.5.4 Online pharmacies
14 Japan HIV Drugs Market
14.1 Japan HIV Drugs Market Historical Value (2017-2023)
14.2 Japan HIV Drugs Market Forecast Value (2024-2032)
14.3 Japan HIV Drugs Market by Medication Class
14.3.1 Market Overview
14.3.2 Multi-Class Combination Drugs
14.3.3 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
14.3.4 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
14.3.5 Protease Inhibitors (PIs)
14.3.6 Entry Inhibitors
14.3.7 HIV Integrase Strand Transfer Inhibitors
14.3.8 Others
14.4 Japan HIV Drugs Market by Distribution Channel
14.4.1 Market Overview
14.4.2 Hospital Pharmacies
14.4.3 Drugs stores and retail pharmacies
14.4.4 Online pharmacies
15 China HIV Drugs Market
15.1 China HIV Drugs Market Historical Value (2017-2023)
15.2 China HIV Drugs Market Forecast Value (2024-2032)
15.3 China HIV Drugs Market by Medication Class
15.3.1 Market Overview
15.3.2 Multi-Class Combination Drugs
15.3.3 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
15.3.4 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
15.3.5 Protease Inhibitors (PIs)
15.3.6 Entry Inhibitors
15.3.7 HIV Integrase Strand Transfer Inhibitors
15.3.8 Others
15.4 China HIV Drugs Market by Distribution Channel
15.4.1 Market Overview
15.4.2 Hospital Pharmacies
15.4.3 Drugs stores and retail pharmacies
15.4.4 Online pharmacies
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication Year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by Year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding and Investment Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 ViiV Healthcare Group of Companies
22.1.1 Financial Analysis
22.1.2 Product Portfolio
22.1.3 Demographic Reach and Achievements
22.1.4 Mergers and Acquisitions
22.1.5 Certifications
22.2 Gilead Sciences, Inc.
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisitions
22.2.5 Certifications
22.3 GSK Plc.
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisitions
22.3.5 Certifications
22.4 Merck & Co., Inc.
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisitions
22.4.5 Certifications
22.5 Bristol-Myers Squibb Company
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisitions
22.5.5 Certifications
22.6 Johnson & Johnson Services, Inc.
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisitions
22.6.5 Certifications
22.7 Boehringer Ingelheim International GmbH
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisitions
22.7.5 Certifications
22.8 AbbVie Inc.
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisitions
22.8.5 Certifications
22.9 Genentech, Inc.
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisitions
22.9.5 Certifications
22.10 Mylan N.V.
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Mergers and Acquisitions
22.10.5 Certifications
22.11 CytoDyn Inc.
22.11.1 Financial Analysis
22.11.2 Product Portfolio
22.11.3 Demographic Reach and Achievements
22.11.4 Mergers and Acquisitions
22.11.5 Certifications
22.12 Daichii Sankyo Company, Limited
22.12.1 Financial Analysis
22.12.2 Product Portfolio
22.12.3 Demographic Reach and Achievements
22.12.4 Mergers and Acquisitions
22.12.5 Certifications
22.13 Pfizer Inc.
22.13.1 Financial Analysis
22.13.2 Product Portfolio
22.13.3 Demographic Reach and Achievements
22.13.4 Mergers and Acquisitions
22.13.5 Certifications
22.14 Shantou Huatai Pharmaceutical Co., Ltd.
22.14.1 Financial Analysis
22.14.2 Product Portfolio
22.14.3 Demographic Reach and Achievements
22.14.4 Mergers and Acquisitions
22.14.5 Certifications
22.15 Shengzhen Chongway Biotechnology Co., Ltd
22.15.1 Financial Analysis
22.15.2 Product Portfolio
22.15.3 Demographic Reach and Achievements
22.15.4 Mergers and Acquisitions
22.15.5 Certifications
List not exhaustive
23 HIV Drugs - Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Company Competitiveness Analysis (Additional Insight)
25.1 Very Small Companies
25.2 Small Companies
25.3 Mid-Sized Companies
25.4 Large Companies
25.5 Very Large Companies
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
The market attained a value of about USD 33.54 billion in 2023 driven by increasing awareness of HIV across the major markets.
The market is anticipated to grow at a CAGR of 4.5% during the forecast period of 2024-2032 and is likely to reach a market value of USD 49.85 billion by 2032.
Factors such as the rising incidence of HIV among people, government initiatives, increasing available treatments in the market, and new developments by market players are major factors aiding market demand.
The surge in FDA approvals to provide effective solutions to the patients is a major market trend. In October 2023, Gilead Sciences, Inc. revealed that Sunlenca® (lenacapavir), their latest drug was well supported to treat multi-drug resistant (MDR) HIV in adults
Drug classes for HIV drugs include multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (Pls), entry inhibitors, and HIV integrase strand transfer inhibitors, among others.
Distribution channels include hospitals pharmacies, drug stores, retail pharmacies, and online pharmacies, among others.
End users in the market include hospitals, and clinics, among others.
The major markets include the United States, EU-4, the United Kingdom, Japan, and China.
Key players involved in the market are Gilead Sciences, Inc., GSK Plc., Merck & Co., Inc., Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Boehringer Ingelheim International GmbH, AbbVie Inc., Genentech, Inc., Mylan N.V., CytoDyn Inc., Daichii Sankyo Company, Limited, Pfizer Inc., Shantou Huatai Pharmaceutical Co., Ltd., Shengzhen Chongway Biotechnology Co., Ltd, and ViiV Healthcare Group of Companies.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.